TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

RECRUITINGPhase 1

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

NCT06211335

Locally Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma+1 more

View study

RECRUITINGPhase 2

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

NCT06636734

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary+20 more

View study

RECRUITINGPhase 2

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

NCT06856213

Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

View study

RECRUITINGPhase 2

Iparomlimab and Tuvonralimab in HNSCC

NCT07090317

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

View study

RECRUITINGPhase 1/2

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

NCT06782555

Metastatic Prostate CancerMetastatic Head and Neck Squamous Cell Carcinoma+1 more

View study

Active Not RecruitingPhase 1/2

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

NCT01468896

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma+1 more

View study